Ruijin Hospital
Clinical trials sponsored by Ruijin Hospital, explained in plain language.
-
New drug firsekibart takes on anakinra in rare inflammatory disease trial
Disease control Recruiting nowThis study tests if a new drug, firsekibart, works better than the current treatment anakinra for adults with Adult-Onset Still's disease (AOSD), a rare inflammatory condition. About 20 participants aged 18-75 will receive either drug to see which controls symptoms and inflammati…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New hope for stomach cancer patients with abdominal spread: targeted drug combo enters trial
Disease control Recruiting nowThis study tests a combination of drugs (LM-302, S-1, and paclitaxel given into the abdomen, with or without cadonilimab) in people with a specific type of advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this treatment helps patients li…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New combo before colon cancer surgery aims for complete tumor disappearance
Disease control Recruiting nowThis study tests whether giving chemotherapy plus an immunotherapy drug before surgery can make colon cancer disappear completely in patients with locally advanced disease. About 56 adults with a specific type of colon cancer will receive the treatment combination, followed by st…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New combo therapy targets tough pancreatic cancer after first treatment fails
Disease control Recruiting nowThis study tests a new approach for people with locally advanced pancreatic cancer whose first chemotherapy stopped working. The treatment combines a procedure that uses electrical pulses to destroy tumor cells (IRE) with an antibody drug that helps the immune system attack the c…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 06, 2026 16:01 UTC